- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
DiaMedica Inc. (TSXV:DMA, OTCQB:DMCAF), announcedis undertaking a non-brokered private placement of up to 4,687,500 Units in the capital of the Company at an issue of $0.16 per Unit for gross proceeds of up to $750,000. The offer is subject to the approval of the TSX Venture exchange.
DiaMedica Inc. (TSXV:DMA, OTCQB:DMCAF), announcedis undertaking a non-brokered private placement of up to 4,687,500 Units in the capital of the Company at an issue of $0.16 per Unit for gross proceeds of up to $750,000. The offer is subject to the approval of the TSX Venture exchange.
According to the company’s press release:
Each Unit will consist of one common share in the capital of the Company (each a “Common Share”) and one-half Common Share purchase warrant (each whole warrant, a “Warrant”), with each Warrant entitling the holder thereof to acquire an additional Common Share at an exercise price of $0.25 per Common Share prior to the expiry date that is two years after the date of issuance. All of the Units issued in connection with the Offering will be subject to a restricted period that expires four months after the issuance date.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.